biochemistri
moscow
vol
abl
inhibit
sever
type
virus
hiv
hcv
influenza
virus
b
coro
navirus
flavivirus
vitro
although
natu
ral
glycopeptid
antibiot
exhibit
pronounc
antivir
activ
test
chemic
remov
sugar
introduct
hydrophob
residu
result
aglycon
pseudo
aglycon
gener
hydrophob
deriv
activ
virus
togeth
vancomycin
teicoplanin
gli
copeptid
antibiot
eremomycin
fig
use
origin
compound
develop
new
gener
antivir
agent
repres
non
nucleosid
inhibitor
rna
replicas
preliminari
find
show
glycopeptid
aglycon
deriv
act
entri
post
entri
stage
viru
infect
cycl
process
viru
penetr
host
cell
replic
provid
specif
interact
viral
structur
non
structur
co
receptor
mechan
antivir
activ
glycopeptid
agli
con
deriv
remain
unclear
viru
entri
cell
life
cycl
depend
use
intracellular
signal
transduct
pathway
ground
screen
sever
hydrophob
glycopeptid
aglycon
deriv
inhibitori
activ
panel
pk
chemic
sigma
aldrich
usa
proqinas
germani
use
compound
librari
eremomycin
obtain
pilot
plant
gaus
institut
new
antibiot
moscow
russia
teicoplanin
teicoplanin
aglycon
kindli
provid
dr
r
ciabatti
dr
malabarba
biosearch
spa
gerenzano
itali
teicoplanin
aglycon
deriv
n
decylamid
amino
n
heptyl
amid
amino
n
decylamid
p
n
n
di
n
butyl
benzylamid
p
n
butylben
zyl
n
heptylamid
n
adamantyl
oxycarbonyl
deriv
n
adamantyl
oxycarbonyl
cyclopropyl
amid
n
butyl
oxycarbonyl
adamantyl
amid
n
butyl
oxycarbonyl
adamantyl
methyl
puriti
ident
use
compound
assess
hplc
spectral
analysi
vitro
pk
activ
assay
human
recombin
pk
activ
recombin
human
pk
assess
radiometr
method
tabl
reaction
mixtur
contain
mm
hepe
naoh
ph
mm
mgcl
mm
mncl
sodium
orthovanad
mm
dithiothreitol
dtt
p
atp
ci
perkinelm
usa
final
volum
enzym
concentr
reaction
mix
ture
follow
aurora
aurora
b
axl
b
raf
met
src
incorpor
radioact
phosphat
follow
substrat
measur
rber
chktide
tetra
lrrwslg
aurora
aurora
b
prk
casein
km
braf
histon
poli
ala
glu
ly
tyr
met
poli
glu
tyr
axl
src
vitro
pk
activ
assay
beckman
coultersagian
multipett
autom
liquid
handler
robot
system
usa
atp
concentr
assay
condit
optim
kinas
well
lot
recombin
protein
verifi
qualiti
recombin
protein
determin
appar
k
atp
valu
condit
use
compound
vitro
test
pk
lot
use
ic
valu
three
ref
erenc
inhibitor
concentr
deter
mine
atp
confirm
reproduc
obtain
result
well
correspond
earlier
publish
data
factor
determin
assay
least
case
exceed
therebi
indic
good
excel
assay
reproduc
reaction
perform
min
stop
ad
h
po
vv
wash
unreact
p
label
incorpor
measur
wallac
microbeta
trilux
micropl
scintil
counter
perkinelm
vitro
pk
activ
assay
tissu
deriv
nativ
purifi
rat
liver
previous
describ
human
recombin
subunit
express
escherichia
coli
use
kinet
analysi
purif
see
phosphoryl
carri
presenc
increas
amount
inhibitor
final
volum
contain
mm
tri
hcl
ph
mm
nacl
mm
mgcl
mm
p
atp
cpmpmol
unless
indic
wise
phosphoryl
substrat
synthet
pep
tide
rrraddsddddd
rrkhaaigddddaysita
respect
reaction
start
ad
kinas
reaction
mixtur
stop
min
ad
h
po
aliquot
reaction
mixtur
spot
onto
phosphocellulos
filter
mann
filter
germani
filter
wash
four
time
ml
mm
h
po
methanol
ml
dri
count
measur
perform
triplic
result
calcul
mean
sem
sem
kinet
analysi
kinet
data
obtain
use
describ
initi
reaction
rate
determin
differ
substrat
atp
concentr
describ
k
valu
calcul
absenc
presenc
increas
inhibitor
concentra
tion
use
lineweaverburk
doubl
reciproc
plot
inhibitori
activ
nine
teicoplanin
deriv
eremomycin
aglycon
deriv
human
pk
aurora
aurora
b
axl
braf
r
met
src
evalu
vitro
either
determin
ic
valu
tabl
mea
ure
enzym
residu
activ
incub
test
compound
tabl
inhibitori
activ
teicoplanin
aglycon
deriv
ativ
teicoplanin
aglycon
teicoplanin
eremomycin
evalu
vitro
nativ
isol
rat
liver
tabl
also
studi
kinet
inhibit
teicoplanin
analogu
exhibit
highest
inhibitori
activ
test
fig
b
compar
inhibitori
activ
studi
gli
copeptid
deriv
pk
discuss
rela
tionship
activ
structur
antivir
activi
tie
test
compound
teicoplanin
aglycon
deriv
hydrophob
teicoplanin
aglycon
carboxamid
contain
var
iou
hydrophob
residu
inhibit
test
human
pk
ic
valu
compound
low
micromolar
rang
tabl
except
inhibit
ic
howev
compound
also
ineffici
rat
liver
protein
kinas
ic
respect
tabl
human
also
less
sensit
teicoplanin
aglycon
deriv
residu
activ
concentr
respect
tabl
compound
show
weak
inhibitori
activ
residu
activ
toward
investig
human
pk
teicoplanin
deriv
demonstrat
ed
signific
inhibitori
activ
test
pk
resid
ual
activ
concentr
among
compound
src
aurora
b
src
strong
inhibitor
suppress
enzymat
activ
use
concentr
tabl
compound
effici
inhibit
isol
rat
liver
ic
compound
almost
inact
enzym
ic
tabl
unlik
nativ
less
sensit
investig
compound
ic
valu
inhibit
compound
much
higher
import
mention
inhibitori
activi
tie
evalu
use
recombin
nativ
protein
tabl
correl
activ
compound
test
hold
true
low
inhibitori
activ
well
higher
inhibitori
activ
compound
kinet
analysi
inhibit
teicoplanin
aglycon
analogu
show
com
pound
suppress
enzym
activ
non
com
petit
mechan
respect
atp
fig
investig
action
mechan
compound
inhibit
studi
constant
atp
con
centrat
presenc
vari
peptid
substrat
concentr
shown
fig
compound
also
show
non
competit
inhibit
respect
peptid
substrat
remark
result
major
kinas
inhibitor
compet
atp
bind
activ
site
inhibitor
non
com
petit
respect
atp
rare
report
eremomycin
aglycon
deriv
eremomycin
agli
con
hexapeptid
show
moder
low
inhibitori
activ
ic
respect
ly
test
human
pk
moder
low
ic
compound
show
remark
abli
high
inhibitori
activ
ic
four
pk
aurora
aurora
b
human
resist
eremomycin
deriv
ic
teicoplanin
aglycon
deriv
ic
relationship
structur
inhibitori
activ
pk
antivir
activ
natur
antibiot
eremomycin
teicoplanin
fig
inhibit
rat
liver
experi
ic
aglycon
deriv
show
moder
low
inhibitori
activ
test
pk
ic
tabl
howev
aglycon
deriv
bear
one
two
hydrophob
residu
fig
b
inhibit
differ
pk
micromolar
concentr
tabl
case
hydrophob
substitu
teicoplanin
aglycon
amid
n
acyl
deriv
amid
n
acyl
deriv
well
eremomycin
aglycon
eremomycin
hexapeptid
amid
essenti
inhibitori
activ
compound
pk
comparison
inhibitori
effici
teicoplanin
eremomycin
aglycon
carboxamid
bear
residu
x
nh
ch
nh
show
teicoplanin
deriv
significantli
activ
test
human
pk
aurora
aurora
b
axl
met
src
eremomycin
deriv
ic
vs
respect
due
differ
structur
teicoplanin
com
parison
eremomycin
aromat
hydrophob
amino
acid
posit
instead
asparagin
asn
addit
chlorin
atom
amino
acid
pep
tide
core
found
earlier
sever
compound
inhibit
differ
pk
experi
ment
suppress
coronavirus
hiv
hiv
felin
infecti
periton
viru
fipv
sever
acut
respiratori
syndrom
associ
coronaviru
sar
cov
flavivirus
includ
hepat
c
viru
hcv
dengu
viru
denv
yellow
fever
viru
yfv
tick
born
enceph
viru
tbev
japanes
enceph
viru
jev
micromolar
concentr
vitro
test
compound
exhibit
cytotox
host
cell
vero
b
cell
sar
cov
denv
yfv
jev
tbev
crfk
cell
fipv
cem
cell
hiv
select
index
cc
ec
cc
compound
concentr
requir
inhibit
host
cell
prolifer
sever
public
known
specif
pk
inhibitor
suppress
viru
replic
exam
ple
chlorophenyl
dihydroxi
hydroxi
methylpiperidin
yl
chromen
one
flavopiridol
first
cdk
inhibitor
human
clinic
trial
block
hiv
replic
also
inhibitor
dimethylamino
tetrabromo
benz
imidazol
dmat
prevent
hcv
product
host
cell
relationship
inhibitori
antivir
activ
glycopeptid
deriv
may
great
inter
est
develop
antivir
drug
sinc
shown
human
cyclin
depend
kinas
cdk
requir
hiv
replic
wherea
src
involv
hcv
replic
eremomycin
aglycon
deriv
contain
ing
hydrophob
residu
investig
anti
hiv
agent
antivir
activ
high
ec
moder
ec
respect
tabl
hydrophob
teicoplanin
aglycon
deriv
amid
effi
cientli
inhibit
human
pk
ic
tabl
well
exhibit
anti
hiv
activ
ec
valu
demon
strate
inhibitori
activ
sever
investig
compound
pk
correl
antivir
activ
display
micromolar
concentr
hydrophob
teicoplanin
aglycon
deriv
strongli
inhibit
human
pk
aurora
b
axl
met
src
control
use
concentr
ic
tabl
select
suppress
hcv
replic
model
subgenom
hcv
replicon
system
cultur
cell
ec
respect
huh
host
cell
interest
data
obtain
teicoplanin
aglycon
deriv
n
butyl
oxycarbonyl
tabl
inhibitori
activ
ic
teicoplanin
eremomycin
teicoplanin
aglycon
deriv
serinethreonin
kina
es
rat
liver
found
compound
target
earli
stage
bindingentri
denv
infect
fact
prevent
denv
entri
host
cell
hcv
replic
impli
mechan
action
inde
demonstr
inhibit
hcv
replic
post
entri
stage
huh
cell
target
establish
yet
howev
consid
denv
hcv
belong
famili
flavivirida
remark
molecul
inhibit
replic
close
ly
relat
virus
affect
two
entir
differ
stage
replic
cycl
manuscript
first
time
evaluat
ed
inhibitori
activ
polycycl
peptid
deriv
ativ
teicoplanin
eremomycin
aglycon
deriv
panel
human
protein
kinas
rat
liver
protein
kinas
teicoplanin
aglycon
analogu
rare
exampl
non
competit
inhibitor
protein
kinas
activ
respect
atp
peptid
substrat
demonstr
kinet
analysi
inhibitori
action
recombin
sever
investig
hydrophob
analogu
poli
cyclic
glycopeptid
antibiot
earlier
found
suppress
replic
hiv
hcv
corona
flavivirus
inhibit
differ
pk
micromolar
concen
tration
rang
tabl
pattern
common
pk
inhibit
antivi
ral
activ
investig
compound
estab
lish
inhibitori
antivir
activ
determin
base
aglycon
structur
ii
hydropho
bic
residu
aglycon
essenti
inhibitori
activ
iti
iii
posit
hydrophob
residu
agli
con
import
iv
number
hydrophob
residu
one
two
import
glycopeptid
aglycon
deriv
promiscu
inhibitor
pk
inhibitori
activ
depend
structur
fact
inhibit
differ
type
pk
may
explain
activ
unrel
virus
hiv
hcv
etc
moreov
level
activ
pk
viru
infect
cell
well
inhibitori
potenti
glycopeptid
aglycon
deriv
abil
per
meat
host
cell
membran
modul
antivi
ral
activ
compound
role
pk
inhibit
antivir
activ
hydrophob
glycopeptid
aglycon
deriv
remain
investig
abil
compound
affect
cellular
protein
kinas
vivo
still
verifi
sinc
atp
concentr
use
vitro
assay
significantli
averag
intracellular
atp
concentra
tion
potenc
kinas
inhibitor
vitro
necessarili
reflect
potenc
cell
therefor
fur
ther
optim
glycopeptid
deriv
aim
improv
potenc
well
demonstr
abil
compound
inhibit
intracellular
protein
kina
es
search
antivir
compound
among
protein
kinas
inhibitor
seem
promis
novel
approach
may
pave
way
new
prospect
drug
discoveri
simultan
provid
valuabl
tool
studi
signal
transduct
viral
replic
moreov
studi
may
use
stand
mechan
antivir
activ
hydrophob
glycopeptid
aglycon
promot
develop
novel
class
pk
inhibitor
base
glycopeptid
antibiot
relat
compound
